Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 23;2(9):100406.
doi: 10.1016/j.xcrm.2021.100406. eCollection 2021 Sep 21.

Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle

Samuel F Bakhoum  1   2 , Charles M Rudin  3   4
Affiliations
Comment

Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle

Samuel F Bakhoum et al. Cell Rep Med. .

Abstract

In the current issue of Cancer Cell, Lan et al.1 demonstrate that a bifunctional fusion protein targeting TGF-β and PD-L1 can synergize with radiation therapy to simultaneously augment tumor control and reduce normal tissue toxicity.

PubMed Disclaimer

Conflict of interest statement

S.F.B. owns equity in, receives compensation from, serves as a consultant for, and sits on the scientific advisory board and board of directors of Volastra Therapeutics, Inc. C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, Astra Zeneca, Epizyme, Genentech/Roche, Ipsen, Jazz, Lilly, and Syros and serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics.

Comment on

References

    1. Lan Y., Moustafa M., Knoll M., Xu C., Furkel J., Lazorchak A., Yeung T.-L., Hasheminasab S.-M., Jenkins M.H., Meister S. Simultaneous targeting of TGF- β and PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021;39 doi: 10.1016/j.ccell.2021.08.008. - DOI - PubMed
    1. Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K.H., de Wit M., PACIFIC Investigators Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017;377:1919–1929. - PubMed
    1. Gray J.E., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K.H., Cho B.C. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J. Thorac. Oncol. 2020;15:288–293. - PMC - PubMed
    1. Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753–791. - PubMed
    1. Tatler A.L., Jenkins G. TGF-β activation and lung fibrosis. Proc Am Thorac Soc. 2012;9:130–136. - PubMed

Substances